$1.60
-0.26-13.98%
Last update: Nov 10, 1:38 PM
Black Diamond Therapeutics Inc (BDTX) Stock Price, Quote, News & History
BDTXNASDAQ
Black Diamond Therapeutics reports Phase 2 silevertinib data, outlines FDA Phase 3 plans, and confirms cash runway extending into late 2028.
You can purchase shares of Black Diamond Therapeutic (NASDAQ:BDTX) through any online brokerage.
Other companies in Black Diamond Therapeutic’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Moderna Inc (NASDAQ:MRNA).
Black Diamond Therapeutic has a consensus price target of $11.90.
The stock price for Black Diamond Therapeutic (NASDAQ: BDTX) is $1.5999 last updated November 10, 2026 at 1:38 PM EST.
There are no upcoming dividends for Black Diamond Therapeutic.
Black Diamond Therapeutic does not have any upcoming earnings scheduled.
There is no upcoming split for Black Diamond Therapeutic.
Black Diamond Therapeutic is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer...
